Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis
et al., Advances in Medical Sciences, doi:10.1016/j.advms.2023.09.007, Sep 2023
Melatonin for COVID-19
12th treatment shown to reduce risk in
December 2020, now with p = 0.0000000099 from 19 studies.
No treatment is 100% effective. Protocols
combine treatments.
6,400+ studies for
210+ treatments. c19early.org
|
Systematic review and meta analysis of 11 COVID-19 studies showing significantly higher clinical improvement and shorter hospitalization and mechanical ventilation time with melatonin treatment.
7 meta-analyses show significant improvements with melatonin for mortality1-4,
mechanical ventilation5,
hospitalization3,5,
improvement5, and
recovery6,7.
Currently there are 19 melatonin for COVID-19 studies, showing 33% lower mortality [19‑44%], 32% lower ventilation [19‑43%], 14% lower ICU admission [-1‑28%], 18% lower hospitalization [3‑30%], and 38% fewer cases [-6‑64%].
1.
Pilia et al., Does melatonin reduce mortality in COVID-19?, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103817.
2.
Tóth et al., Melatonin as adjuvant treatment in COVID-19 patients. A meta-analysis of randomized and propensity matched studies, Signa Vitae, doi:10.22514/sv.2023.076.
3.
Amin et al., Role of Melatonin in Management of COVID-19: A Systematic Review, Microbes, Infection and Chemotherapy, doi:10.54034/mic.e1982.
4.
Qin et al., Benefits of melatonin on mortality in severe-to-critical COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials, Clinics, doi:10.1016/j.clinsp.2025.100638.
5.
Taha et al., Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis, Advances in Medical Sciences, doi:10.1016/j.advms.2023.09.007.
Taha et al., 22 Sep 2023, peer-reviewed, 8 authors.